What is Nucleome Therapeutics?
Nucleome Therapeutics is an innovative immunology company dedicated to tackling the root causes of immune-mediated inflammatory diseases. Leveraging cutting-edge 3D genomics technology, the company constructs a detailed data atlas of immune system dysregulation by linking disease-associated genetic variants to the genes they impact. Operating from state-of-the-art facilities in Oxford, UK, Nucleome's expert scientists are focused on validating these findings and advancing therapeutics designed to restore patient health. The company's pipeline is strategically oriented towards identifying causal genes that drive inflammation, aiming to pioneer a new generation of targeted treatments.
How much funding has Nucleome Therapeutics raised?
Nucleome Therapeutics has raised a total of $42.4M across 1 funding round:
Series A
$42.4M
Series A (2022): $42.4M with participation from Johnson & Johnson, Merck Ventures, and Pfizer Ventures
Key Investors in Nucleome Therapeutics
Johnson & Johnson
Johnson & Johnson is a global healthcare giant with a broad portfolio in pharmaceuticals and medical technologies, focusing on areas like oncology and immunology.
Merck Ventures
M Ventures, the corporate venture capital arm of Merck, strategically invests in innovative technologies that can significantly impact its core business areas, with a focus on early-stage investments.
Pfizer Ventures
Pfizer Ventures is the venture capital arm of Pfizer, investing in companies that align with Pfizer's strategic interests in advancing healthcare solutions.
What's next for Nucleome Therapeutics?
With its recent major strategic investment, Nucleome Therapeutics is poised for significant expansion and acceleration of its therapeutic development pipeline. The substantial backing from prominent investors suggests a strong validation of the company's unique approach to understanding and treating immune-mediated inflammatory diseases through advanced genetic insights. This capital will likely fuel further research and development, clinical trial progression, and the scaling of its innovative 3D genomics platform. The company's focus on identifying causal genes positions it to make substantial contributions to precision medicine in immunology.
See full Nucleome Therapeutics company page
